HS
BDTX icon

HighVista Strategies’s Black Diamond Therapeutics BDTX Stock Holding History

HighVista Strategies’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-26,770
Closed -$649K – 125
2021
Q1 		$649K Buy
+26,770
New +$722K 0.48% 51
2020
Q4 		– Sell
-16,391
Closed -$496K – 118
2020
Q3 		$496K Buy
+16,391
New +$499K 0.36% 49

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighVista Strategies's BDTX Position: Q2 2021 in Review

HighVista Strategies sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 26,770 shares — an estimated $649K sold.

HighVista Strategies first reported a position in BDTX in Q3 2020 and held it in 2 quarters. The position peaked at $649K in Q1 2021. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

  • HighVista Strategies reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 26,770 Black Diamond Therapeutics shares in Q2 2021, an estimated $649K.
  • HighVista Strategies first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 2 quarters.
  • HighVista Strategies's Black Diamond Therapeutics position peaked at $649K in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.